A new method for editing genes and their regulation in mice
Official title: A modular system for murine CRISPR genome and epigenome editing
Funded at Boston Children's Hospital · NIH-11145318 · Data updated 2026-11-12
This study is working on new ways to change genes in mice using a special technology called CRISPR, which could help scientists better understand how genes work and how they relate to diseases.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Children's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 15, 2025 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $222,500 |
| NIH project number | 1R21OD037909-01A1 |
| Project ID | NIH-11145318 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with genetic conditions that could benefit from advanced gene editing technologies.
✕Less likely to help
Patients with conditions that are not related to genetic mutations or do not require gene editing may not benefit from this research.
What this research studies
This research focuses on developing advanced tools for editing genes and their regulatory elements in mice using CRISPR technology. By creating mouse models that express specific CRISPR components, the researchers aim to enhance the precision and efficiency of genetic modifications. The approach involves using adeno-associated virus (AAV) vectors to deliver these editing tools, allowing for more effective and uniform gene editing compared to traditional methods. This innovative strategy could lead to significant advancements in understanding genetic functions and diseases.
Why it matters
Potential benefit: If successful, this research could lead to more effective gene therapies and treatments for genetic disorders.
How similar studies have gone: Previous research has shown promising results using CRISPR technology for gene editing, indicating that this approach has the potential for success.
Where this research is happening
-
Boston Children's Hospital
Boston, United States Active
Researchers
- Principal investigator: Pu, William Tswenching — Boston Children's Hospital
- Study coordinator: Pu, William Tswenching
Related research
Other NIH-funded projects on the same topics.
-
Targeting the brain’s fluid system to treat post-hemorrhagic hydrocephalus
This grant explores a new approach to treating post-hemorrhagic hydrocephalus by studying how the brain’s fluid system and immune cells manage CSF after a brain bleed.
-
National Spina Bifida Patient Registry at Boston Children’s Hospital
A patient-focused registry project at Boston Children’s Hospital will collect and study information from people with spina bifida to improve care and outcomes.
-
Severe Chronic Neutropenia Registry for Patients
A patient-facing registry that tracks severe chronic low neutrophil counts to improve understanding and care for people with this condition.
-
Severe Chronic Neutropenia Registry to Improve Care
A patient-focused registry gathers information from adults with severe chronic neutropenia to better understand infections, treatments, and outcomes over time.
-
Severe Chronic Neutropenia Registry: Finding Better Ways to Prevent Infections
A patient-focused registry at a leading hospital helps people with severe chronic neutropenia learn how the condition progresses and how treatments work over time.
-
Exploring epilepsy genes in zebrafish to understand human brain seizures
A study in zebrafish will model human epilepsy genes to help explain how certain brain mutations contribute to seizures.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.